Multidrug-resistant Klebsiella pneumoniae: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil

Imagem de Miniatura
Arquivos
art_BOSZCZOWSKI_Multidrugresistant_Klebsiella_pneumoniae_genetic_diversity_mechanisms_of_resistance_2019.PDF (279.83 KB)
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.61, article ID UNSP e29, 9p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Increased resistance to polymyxin in Klebsiella pneumoniae (ColRKP) has been observed. Molecular epidemiology, as well as the clinical impact of these difficult to treat pathogens need to be better characterized. We present the clinical outcomes of 28 patients infected by ColRKP in a tertiary hospital. Isolates with MIC >2 by Vitek 2 were confirmed by the microdilution broth test. Polymerase chain reaction (PCR) was performed for bla(KPC), bla(NDM), bla(OXA-48), and bla(mcr-1) genes in the isolates, and Whole Genome Sequencing (WGS) was performed in six isolates. Seventeen (61%) patients were female and the mean age was 50 years old. In-hospital and 30-day mortality were 64% (18/28) and 53% (15/28), respectively. Central line-associated bloodstream infection in addition to bacteremia episodes due to other sources were the most frequent (61%). Mean APACHE and Charlson comorbidity index were 16 and 5, respectively. Twenty patients (71%) received at least one active drug and ten (35%) received two drugs: tigecycline 46% (13/28); amikacin 21% (6/28) and fosfomycin 3% (1 case). Twenty-six out of 28 tested cases were positive for bla(KPC) Eight different clusters were identified. Four STs were detected (ST1, ST23, ST340, and ST437). Mutations on pmrA, arnB udg, and yciM genes were present in all six isolates submitted to WGS; /pxMand mgrB mutations were also detected in all but one isolate. In conclusion, we observed resistance to polymyxin in severely ill patients mostly from intensive care units and/or immunosuppressed patients with high mortality rates in whom a diversity of ColRKP clusters was identified and might indicate selective pressure.
Palavras-chave
Colistin resistance, Hospital epidemiology, Antibiotic therapy, Genome sequencing, Polymyxins
URI
https://observatorio.fm.usp.br/handle/OPI/33107
Referências
  1. Antonelli A, 2016, DIAGN MICR INFEC DIS, V86, P30, DOI 10.1016/j.diagmicrobio.2016.06.002
  2. Caneiras C, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7040096
  3. Cannatelli A, 2014, ANTIMICROB AGENTS CH, V58, P4399, DOI 10.1128/AAC.02555-14
  4. Cannatelli A, 2013, ANTIMICROB AGENTS CH, V57, P5521, DOI 10.1128/AAC.01480-13
  5. Cassu-Corsi D, 2015, BRAZ J INFECT DIS, V19, P102, DOI 10.1016/j.bjid.2014.08.008
  6. Clinical and Laboratory Standards Institute, 2014, PERF STAND ANT SUSC
  7. Carrillho CMDD, 2017, DIAGN MICR INFEC DIS, V87, P253, DOI 10.1016/j.diagmicrobio.2016.11.007
  8. Elemam A, 2010, J CLIN MICROBIOL, V48, P3558, DOI 10.1128/JCM.01106-10
  9. Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323
  10. Giani T., 2013, Eurosurveillance, V18, P20489
  11. Gomez-Simmonds A, 2016, ANTIMICROB AGENTS CH, V60, P3601, DOI 10.1128/AAC.03007-15
  12. Jayol A, 2014, ANTIMICROB AGENTS CH, V58, P4762, DOI 10.1128/AAC.00084-14
  13. Kim SY, 2014, CURR MICROBIOL, V69, P37, DOI 10.1007/s00284-014-0549-0
  14. Larsen MV, 2012, J CLIN MICROBIOL, V50, P1355, DOI 10.1128/JCM.06094-11
  15. Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7
  16. Sampaio JLM, 2016, BRAZ J MICROBIOL, V47, P31, DOI 10.1016/j.bjm.2016.10.002
  17. Mezzatesta ML, 2011, CLIN MICROBIOL INFEC, V17, P1444, DOI 10.1111/j.1469-0691.2011.03572.x
  18. Monteiro J, 2009, ANTIMICROB AGENTS CH, V53, P333, DOI 10.1128/AAC.00736-08
  19. Morales AS, 2012, SCI WORLD J, DOI 10.1100/2012/109795
  20. Olaitan AO, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00643
  21. Oliveira C, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.262.6522
  22. Pavez M, 2009, ANTIMICROB AGENTS CH, V53, P2702, DOI 10.1128/AAC.00089-09
  23. Neto LVP, 2019, J ANTIMICROB CHEMOTH, V74, P177, DOI 10.1093/jac/dky406
  24. Rossi F, 2017, BRAZ J INFECT DIS, V21, P98, DOI 10.1016/j.bjid.2016.09.011
  25. Samonis G, 2014, EUR J CLIN MICROBIOL, V33, P1505, DOI 10.1007/s10096-014-2097-8
  26. Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153
  27. Zankari E, 2012, J ANTIMICROB CHEMOTH, V67, P2640, DOI 10.1093/jac/dks261
  28. Zhang ZJ, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0441-y

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03